Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K J Parlevliet

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|August 8, 1987
[Wegener's disease]K J Parlevliet, W Bronsveld
Transplant International : Official Journal of the European Society for Organ Transplantation|September 1, 1992
Monoclonal antibodies in renal transplantation: a reviewK J Parlevliet, P T Schellekens
The Quarterly Journal of Medicine|January 1, 1988
Antibodies to components of neutrophil cytoplasm: a new diagnostic tool in patients with Wegener's granulomatosis and systemic vasculitisK J Parlevliet, S C Henzen-Logmans, P L Oe, et al.
The Journal of Clinical Investigation|June 1, 1994
In vivo effects of IgA and IgG2a anti-CD3 isotype switch variantsK J Parlevliet, I J ten Berge, S L Yong, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 1, 1994
Low-dose OKT3 induction therapy following renal transplantation: a controlled studyK J Parlevliet, R J ten Berge, M H Raasveld, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 23, 2007
Guidelines for the optimal use of muromonab CD3 in transplantationI J ten Berge, K J Parlevliet, M H Raasveld, et al.
Transplantation Proceedings|December 1, 1994
Toxicity of IgA anti-CD3 isotype switch variant in vivoI J ten Berge, K J Parlevliet, S L Yong, et al.
Transplantation Proceedings|December 21, 2002
No long-term benefit of low-dose OKT3 induction therapy in non to moderately immunized renal allograft recipientsF J Bemelman, S Yong, K J Parlevliet, et al.
Clinical and Experimental Immunology|February 1, 1995
Effects of anti-CD3 monoclonal antibodies on functional activity of lymphocytes: studies in vivo and in vitroK J Parlevliet, M E Chamuleau, S L Yong, et al.
Transplant Immunology|January 1, 1994
Sequestration of labelled granulocytes in the lungs following administration of OKT3 is dose-dependentF J Bemelman, K J Parlevliet, P T Schellekens, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Nederlands Tijdschrift Voor Geneeskunde|August 8, 1987
[Wegener's disease]K J Parlevliet, W Bronsveld
Transplant International : Official Journal of the European Society for Organ Transplantation|September 1, 1992
Monoclonal antibodies in renal transplantation: a reviewK J Parlevliet, P T Schellekens
The Quarterly Journal of Medicine|January 1, 1988
Antibodies to components of neutrophil cytoplasm: a new diagnostic tool in patients with Wegener's granulomatosis and systemic vasculitisK J Parlevliet, S C Henzen-Logmans, P L Oe, et al.
The Journal of Clinical Investigation|June 1, 1994
In vivo effects of IgA and IgG2a anti-CD3 isotype switch variantsK J Parlevliet, I J ten Berge, S L Yong, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 1, 1994
Low-dose OKT3 induction therapy following renal transplantation: a controlled studyK J Parlevliet, R J ten Berge, M H Raasveld, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 23, 2007
Guidelines for the optimal use of muromonab CD3 in transplantationI J ten Berge, K J Parlevliet, M H Raasveld, et al.
Transplantation Proceedings|December 1, 1994
Toxicity of IgA anti-CD3 isotype switch variant in vivoI J ten Berge, K J Parlevliet, S L Yong, et al.
Transplantation Proceedings|December 21, 2002
No long-term benefit of low-dose OKT3 induction therapy in non to moderately immunized renal allograft recipientsF J Bemelman, S Yong, K J Parlevliet, et al.
Clinical and Experimental Immunology|February 1, 1995
Effects of anti-CD3 monoclonal antibodies on functional activity of lymphocytes: studies in vivo and in vitroK J Parlevliet, M E Chamuleau, S L Yong, et al.
Transplant Immunology|January 1, 1994
Sequestration of labelled granulocytes in the lungs following administration of OKT3 is dose-dependentF J Bemelman, K J Parlevliet, P T Schellekens, et al.
Pageof 2